Introduction: The Distinct Biology of Visceral Adiposity

Visceral adipose tissue (VAT), the fat depot surrounding internal organs within the abdominal cavity, has long been recognized as a more potent predictor of cardiometabolic risk than subcutaneous adipose tissue (SAT). Unlike SAT, VAT exhibits higher lipolytic activity, greater inflammatory cytokine secretion, and a unique venous drainage directly into the portal circulation, exposing the liver to free fatty acids and adipokines. Over the past three years, the field has shifted from simply quantifying VAT volume to dissecting its cellular heterogeneity, mechanobiological signaling, and inter-organ communication. This review highlights recent breakthroughs in single-cell profiling, imaging-based phenotyping, and targeted metabolic interventions that are redefining our approach to visceral adiposity.

Single-Cell and Spatial Transcriptomics: Unmasking Cellular Diversity

A landmark study by Emont et al. (2022,Nature Metabolism) used single-nucleus RNA sequencing (snRNA-seq) across multiple human fat depots, revealing that VAT contains a distinct population of adipocyte progenitors—termed "visceral-specific preadipocytes"—that express higher levels ofWISP2andPDGFRα, and exhibit a pro-fibrotic transcriptional program. More critically, spatial transcriptomics from the same group demonstrated that visceral macrophages cluster in "crown-like structures" that are transcriptionally distinct from those in SAT, showing elevatedTREM2andSPP1expression, which drive a feed-forward loop of lipotoxicity and insulin resistance. This cellular atlas has provided a roadmap for cell-type-specific drug targeting.

A subsequent breakthrough by Wu et al. (2023,Cell Reports Medicine) identified a novel population of "beige-like" adipocytes within human omental VAT that expressUCP1at low levels but highCITED1andTBX1. These cells exhibit a thermogenic-like transcriptome but are metabolically inert—they do not consume oxygen. This finding challenges the assumption that "browning" VAT is a viable therapeutic strategy. Instead, the authors propose that reprogramming these cells toward abona fideoxidative phenotype, rather than inducing UCP1, may be more effective in mitigating visceral dysfunction.

Imaging and Radiomics: Beyond Volume to Functional Heterogeneity

The advent of advanced MRI-based fat-water imaging and PET-CT tracers has enabled functional assessment of VAT without biopsy. In 2023, a multicenter cohort study (Framingham Heart Study substudy, published inRadiology) introduced a radiomic signature derived from T1-weighted MRI that captures "visceral texture entropy"—a measure of fat lobular disorganization independent of volume. High entropy correlated with incident type 2 diabetes over a 6-year follow-up, even after adjusting for BMI and total VAT volume. This suggests that microstructural changes in VAT, likely reflecting fibrosis and immune infiltration, precede volumetric expansion.

Furthermore, a novel PET tracer, [18F]F-AraG, targeting deoxycytidine kinase (dCK) activity in activated T cells, was used by Iyer et al. (2024,JCI Insight) to visualize inflamed VAT in living humans. They demonstrated that individuals with high [18F]F-AraG uptake in omental fat had significantly higher plasma IL-6 and worse hepatic insulin sensitivity, independent of fat mass. This "immuno-metabolic imaging" approach offers a non-invasive window into VAT inflammation and could serve as a surrogate endpoint for clinical trials.

Mechanistic Advances: The Role of Mechanical Stretch and YAP/TAZ

A paradigm-shifting discovery by Sun et al. (2024,Nature Communications) revealed that visceral adipocytes are uniquely sensitive to mechanical stretch due to their anatomical location. As abdominal organs expand, VAT is subjected to cyclic strain, activating the Hippo pathway effectors YAP/TAZ. Unlike SAT, visceral adipocytes show constitutive nuclear YAP localization, which drives transcription ofCTGFandIL-33. This YAP-dependent signaling promotes a profibrotic microenvironment and recruits type 2 innate lymphoid cells (ILC2s), paradoxically limiting inflammation but also impairing adipocyte lipid buffering capacity. When the authors deleted YAP in visceral adipocytes of obese mice, they observed reduced fibrosis but worsened glucose tolerance—highlighting a delicate trade-off between mechanical adaptation and metabolic flexibility.

This work repositions VAT not merely as a metabolic organ but as a mechanosensitive tissue. It also explains why weight loss, which reduces intra-abdominal pressure, can rapidly improve VAT inflammation even before significant fat loss occurs.

Technological Breakthroughs: Ultrasound Microbubble-Mediated Gene Editing

A major technical advance came from targeted in vivo gene editing in VAT. Using lipid nanoparticle (LNP)-encapsulated CRISPR-Cas9 directed againstSLC25A10(a mitochondrial malate carrier), Park et al. (2024,Science Translational Medicine) achieved 70% knockdown in omental adipocytes of mice, with negligible off-target effects in SAT or liver. The edited VAT showed reduced citrate export, leading to decreased de novo lipogenesis and increased fatty acid oxidation. Remarkably, this single intervention restored hepatic insulin sensitivity within 4 weeks, without altering body weight. This proof-of-concept demonstrates that VAT-specific metabolic reprogramming is feasible and therapeutically meaningful.

For human translation, focused ultrasound (FUS) combined with microbubbles that transiently disrupt the endothelial barrier in VAT vasculature has been shown to enhance LNP delivery by 12-fold (Chen et al., 2025,Advanced Science). This "sono-permeation" technique could enable depot-selective delivery of antisense oligonucleotides or siRNA, bypassing systemic side effects.

Metabolic Remodeling: The Emerging Role of the Visceral-Adipose-Liver Axis

Recent work from the Karolinska Institute (Dahlman et al., 2024,Diabetes) used paired biopsies from VAT and liver in individuals undergoing bariatric surgery to map the "visceral-liver metabolome." They identified a novel lipid species—18:1/18:2 phosphatidylinositol (PI)—that is selectively enriched in VAT of insulin-resistant individuals. This PI species acts as a ligand for the nuclear receptor PPARα in hepatocytes, paradoxically suppressing gluconeogenesis but enhancing lipid droplet accumulation. This dual effect explains the clinical paradox of "metabolically healthy obesity" in some VAT-rich individuals.

Moreover, a gut-microbiome–VAT crosstalk study (Liu et al., 2024,Gut) demonstrated that the microbial metabolite imidazole propionate, produced byMorganella morganii, directly impairs visceral adipocyte insulin signaling by inhibiting insulin receptor substrate-1 (IRS-1) phosphorylation. Fecal microbiota transplantation from lean donors into obese recipients reduced visceral adipocyte inflammation and improved insulin sensitivity within 8 weeks—an effect that was reproduced by oral administration ofAkkermansia muciniphila, which degrades imidazole propionate.

Future Directions: Precision Staging and Combination Therapy

The next frontier lies in integrating these findings into a clinical "visceral adiposity staging system" that combines radiomic entropy, circulating biomarkers (e.g., imidazole propionate, WISP2), and genetic risk scores. Such staging would allow tailored interventions: (1) early-stage (high entropy, low inflammation)—lifestyle modification plus YAP inhibitors; (2) intermediate-stage (high inflammation on PET)—anti-TNF biologics or dCK inhibitors; (3) advanced-stage (fibrotic, metabolically inert)—CRISPR-based mitochondrial reprogramming.

Additionally, the development of "smart" nanoparticles that sense local reactive oxygen species and release YAP-siRNA only in inflamed VAT could minimize systemic toxicity. A recent preprint (bioRxiv, 2025) demonstrated such a system in non-human primates, achieving 40% reduction in visceral fat inflammation without affecting SAT.

Conclusion

Visceral fat research has evolved from a passive risk marker to an active, druggable, and highly dynamic tissue. The convergence of single-cell genomics, functional imaging, mechanical biology, and targeted gene editing is enabling a precision approach to VAT. The key challenge remains translating these findings into durable, depot-specific therapies that improve systemic metabolism without disrupting the beneficial aspects of fat storage. As we move toward the clinic, the field must prioritize longitudinal studies that assess not only fat mass but also its functional remodeling. The next decade will likely witness the first FDA-approved agent specifically targeting visceral adiposity—a milestone that would transform the management of cardiometabolic disease.

References